About Us



  • Doctor of Veterinary Medicine, Iowa State University, 1985


Boehringer Ingelheim Vetmedica, Inc., St. Joseph, MO (2003 to 2014)

  • Oversaw and assisted with study design and protocol development, implementation of studies and writing of final reports for clinical and non-clinical studies (efficacy and safety) to aid in the licensure of new biological products (EU and USDA) and reference qualification of currently licensed biological products
  • Located, interviewed, trained and consulted with Study Investigators and Contract Research Organizations
  • Managed the Bio Clinical Development team with respect to research and pivotal clinical studies (safety and efficacy)
  • Managed timelines and budgets of multiple projects

Colorado Serum Company, Denver, CO (1990 to 2002)

  • Liaised with independent research laboratories to evaluate the market potential of new vaccines, and recommended which products had the potential to proceed to research and development
  • Designed, implemented and monitored clinical studies (safety and efficacy) to aid in the licensure of new biological products and defend currently licensed products
  • Manager of Technical Services and Manager of Clinical Studies; assisted with Regulatory Affairs
  • Supervised animal care staff
  • Directed antisera production
  • Served as Attending Veterinarian for company IACUC
  • Study Investigator for in-house clinical studies

Huron Animal Hospital Denver, CO (1985 to 1990)

  • Associate veterinarian at a busy small animal hospital and served as primary soft tissue and orthopedic surgeon

Publications, Posters and Presentations:

  • “An overview of a commercially available vaccine for Corynebacterium pseudotuberculosis”, USAHA, Sheep and Goat Committee, Louisville, Kentucky, 1997
  • “Vaccines for goats”, American Dairy Goat Association Convention; Tucson,

Arizona, 1997

  • Piontkowski MD, Shivvers DW. Evaluation of a commercially available vaccine against Corynebacterium pseudotuberculosis for use in sheep. J Am Vet Med Assoc, 1998 212:1765-1768.
  • “Progress in vaccination against bovine brucellosis: a new vaccine RB51, which does not react in standard serological tests”, National Seminar on Brucellosis of Cattle, Sheep and Goats; Rabat, Morocco, 1998
  • “US experiences with RB51”, OIE IV Seminar on Harmonization for registration and control of veterinary medicines; Salvador, Brazil, 1998
  • Participant on panel “PAHO/WHO Expert consultation on Brucellosis vaccines and vaccine strategies for Brucellosis control/eradication programs”; Santiago, Chile, 1999
  • Eichmeyer M, Roof M, Piontkowski M, Hayes P, Saltman R. “Efficacy evaluation of a Mycoplasma Hyopneumoniae Bacterin in a mixture with a Porcine Circovirus Type 2 Vaccine”. 20th IPVS Congress, Durban, South Africa, 22-26 June 2008
  • Piontkowski, M, Ohnesorge C, I von Richthofen. “Ingelvac MycoFLEX® provides at least 26 weeks duration of immunity”. 2008 Lehman Conference, St. Paul, MN, 20-23 September 2008
  • Piontkowski, M, Eichmeyer M. “Multi-site field safety study of a trivalent vaccine mixture”. 2010 Lehman Conference, St. Paul MN, 19-21 September 2010
  • Eichmeyer M, Roof M, Piontkowski M, Robb E. “Efficacy of Ingelvac® PRRS  MLV when rehydrated with a combination of Ingelvac® MycoFLEX™ and Ingelvac® CircoFLEX™. 2010 Lehman Conference, St. Paul MN, 19-21 September 2010
  • Glover S, Anderson C, Piontkowski M, Ng T. Canine Parvovirus (CPV) Type 2b vaccine protects puppies with maternal antibodies to CPV when challenged with virulent CPV-2c virus. Intern J Appl Res Vet Med, 2012 10:217-224.


  • US Patent No.: 8,765,142
  • US Patent No.: 8,865,183
  • EU Patent No.: EP2675475
  • EU Patent No.: EP2481420
  • EU Patent No.: EP2094872

Professional Affiliations:

  • American Association of Veterinary Immunologists
  • American Veterinary Medical Association
  • Kansas Veterinary Medical Association

State Veterinary Licenses:

  • Kansas
  • Colorado